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Abstract 
 
Background: Although previous studies have implicated tissue CD4+ T-cells in the 
development and maintenance of the inflammatory response in asthma, little is known about 
the role of CD8+ T-cells. There is now accumulating evidence that miRNAs and other non-
coding RNAs are important regulators of T-cell function.     
Objectives: To use transcriptomics to determine the activation state of circulating CD4+ and 
CD8+ T-cells in non-severe and severe asthma.  
Methods: mRNA and non-coding RNA expression in circulating T cells was measured by 
microarray and/or quantitative real time-polymerase chain reaction. 
Results: Comparison of mRNA expression showed widespread changes in the circulating 
CD8+ but not CD4+ T-cells from patients with severe asthma. No changes were observed in the 
CD4+ and CD8+ T-cells in non-severe asthmatics versus healthy controls. Bioinformatics 
analysis showed that the changes in CD8+ T-cell mRNA expression were associated with 
multiple pathways involved in T-cell activation. As with mRNAs, we also observed 
widespread changes in expression of non-coding RNA species including natural antisense, 
pseudogenes, intronic long ncRNAs and long intergenic long ncRNAs in CD8+ T-cells from 
severe asthmatics. Measurement of the miRNA expression profile showed selective down-
regulation of miR-28-5p in CD8+ T-cells and reduction of miR-146a and miR-146b in both 
CD4+ and CD8+ T-cells. 
Conclusions: Severe asthma is associated with the activation of circulating CD8+ T-cells but 
not CD4+ T-cells. This response is correlated with the down-regulation of miR-146a/b and 
miR-28-5p as well as changes in the expression of multiple species of long non-coding RNA 
that might regulate CD8+ T-cell function.     
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Clinical Implications 
Severe asthma is associated with the activation of circulating CD8+ T-cells and targeting this 
response might provide a novel therapeutic approach.  
 
Capsule Summary 
Examination of the transcriptome has demonstrated widespread changes in the mRNA and 
non-coding RNA expression in circulating CD8+ T-cells but not CD4+ T-cells in patients with 
severe asthma.  
 
Key Words: severe asthma, CD8+ T-cells, transcriptome, noncoding RNA, microRNA 
 
Abbreviations: IL, interleukin; miRNA, microRNA; Th, T help; TCR, T-cell receptor 
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Introduction 
 
Asthma is characterised by reversible airway obstruction, re-modelling and inflammation and 
is one of the most common chronic allergic diseases affecting 300 million people worldwide 
and causing approximately 180,000 deaths per year 1. Most patients with asthma respond well 
to anti-inflammatory treatment with inhaled corticosteroid therapy. However, 5-10% of 
patients experience ongoing symptoms of asthma despite taking corticosteroid treatments, 
often in combination with long-acting -agonists and other controller therapies. These patients 
have been labelled as having severe asthma or therapy resistant asthma and form a 
heterogeneous group of patients that can be divided  into distinct phenotypes 2;3.  
 
Although the underlying mechanisms that drive asthma are still an area of contention, T-cells 
have been proposed to contribute to the induction and maintenance of the inflammatory 
response. Following their early identification in bronchoalveolar lavage (BAL), much work 
has focused upon the importance of the T-helper 2 (Th2) CD4+ T-cells 4. These cells are 
activated following the interaction between the T-cell receptor (TCR) and peptide antigen 
presented in the context of MHC class II molecules expressed by airway dendritic/epithelial 
cells. In turn, this stimulates the release of Th2 cytokines including IL-4, IL-5, IL-9 and IL-13 
that contribute to development of many of the features of asthma including airways hyper-
responsiveness, mucus hyper-secretion, airway eosinophilia and B-cell activation 5;6. 
Significantly, recent studies have also implicated roles for other sub-types of CD4+ T-cells 
including the regulator T-cells (Treg), Th9, Th17, Th22,  T-cells and natural killer T-cells 
(NKT), although the majority of these studies have been performed in animal models and their 
role in human asthma remains to be confirmed 5;6.  
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Unlike CD4+ T-cells, little is known about the role of CD8+ T-cells, which are normally 
associated with the recognition and destruction of cells that are infected with viruses and other 
intracellular pathogens.  Previous studies in patients have shown the presence of CD8+ in the 
BAL and sputum of asthmatics whilst increased CD8+ T-cell numbers were noted in patients 
with status asthmaticus 7-9.  In addition, animal studies have shown that CD8+ T-cells 
contribute towards the development of allergen-induced airway hyper-responsiveness and 
pulmonary inflammation 10.  
 
In this report, we have adopted a transcriptomics based approach to investigate the activation 
state of circulating CD4+ and CD8+ T-cells in severe asthma and to identify potential 
targets/pathways that might provide novel therapeutic targets. In addition, we have 
investigated whether any changes in mRNA expression are regulated at the post-transcriptional 
level by microRNA expression and whether there are changes in the expression of other non-
coding RNAs including antisense, pseudogenes, long intronic non-coding RNA and long 
intergenic non-coding RNAs. Significantly, measurement of the mRNA expression profile has 
shown activation of the circulating CD8+ but not CD4+ T-cell populations in severe asthma. 
No significant changes in mRNA expression were observed in the CD4+ and CD8+ T-cells 
obtained from non-severe asthmatics. As with the mRNAs, we have shown widespread 
changes in expression of natural antisense, pseudogenes, long intronic non-coding RNA and 
long intergenic non-coding RNA within the CD8+ population from severe asthmatics. In 
addition, we observed reduced expression of miR-28-5p in CD8+ T-cells and down-regulated 
expression of miR-146a and miR-146b in both CD4+ and CD8+ T-cells. Overall, these 
observations have revealed that activation of CD8+ T-cells might have an important role in the 
pathogenesis of severe asthma and that this activation maybe regulated through changes in 
expression of multiple classes of non-coding RNAs. 
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Methods 
 
T-cell isolation 
 
Human CD4+ and CD8+ T cell were isolated by negative selection using Miltenyi beads and 
MACS Vario magnetic cell separation apparatus. T-cell purity was assessed by FACS using 
anti-CD4-FITC and anti-CD8-PE (Miltenyi) using CellQuest software. 
 
Microarray Analysis of mRNA and non-coding RNA expression  
Expression profiling was performed using the Affymetrix U133 Plus 2.0 microarrays at 
AROS, Denmark. Total RNA was extracted using the mirVanaTM miRNA isolation kit 
(Ambion Europe) eluted in 50 l RNase-free water (Promega UK) and purity was measured 
using a BioTek PowerWave XS (SSi Robotics, U.S.A.) spectrophotometer and Agilent 
Bioanalyser, which showed RIN values > 9.5. Raw data were analysed using 
GeneSpringGX10 and then R/Bioconductor.  Arrays data were then normalised using robust 
multi-array (rma) and batch effects corrected using the ComBat R package 11.  Data was 
filtered to remove probes which had low expression in all arrays (rma signal value of < 4 was 
removed).  Differential gene regulation was determined by taking the output from a shrinkage 
t-test 12 and then computing the p-values and q-values (FDR) using 'fdrtool' 13.  The cutoff 
used for significance is FDR < 0.05 which is a 5% false discovery rate.  The p-values are 
shown to allow readers to discern different rankings of genes where the FDR value is < 0.05.  
Raw microarray data has been deposited with GEO (Accession number XXXX).    
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Changes in antisense, pseudogenes, long intronic non-coding RNA and long intergenic non-
coding RNAs expression were determined by mapping non-annotated probes onto the human 
genome (GRCh37) using Ensembl (http://www.ensembl.org/index.html).  
 
qPCR measurement of miRNA and mRNA expression 
 
miRNA expression profiling was undertaken using the two-step Applied Biosystems TaqMan® 
RT-PCR protocol and normalised to RNU44 as previously described (14). mRNA expression 
levels was determined by TaqMan® RT-PCR using on Assays on Demand (Applied 
Biosystems). Alternatively, mRNA levels were determined using the Power SYBR® Green 
PCR mix (Applied Biosystems) using the listed probes (MWG-Biotech).  The separate well, 
2−(ΔΔCt) method was used to determine relative-quantitative levels of individual miRNAs and 
mRNAs 
  
The following primer sequences were used for the mRNA RT-PCR. LCN:  Forward: 
CACCCTCTACGGGAGAACCAAGGA; Reverse: ACCTGTGCACTCAGCCGTCGATA;  
S100A8 Forward: CACATTCCTGTGCATTGAGGGGTTA; Reverse: 
GGGTGTCAAAATGCCCCTTCCG;  
S100P Forward: CAGGCTTCCTGCAGAGTGGAAAAGA; Reverse: 
GCAGACGTGATTGCAGCCACGA;  
CAMP Forward: AGACACGCCAAAGCCTGTGAGCTT; Reverse: 
TTCACCAGCCCGTCCTTCTTGAAGT;  
BPI: Forward: TGCAGAAGGAGCTGAAGAGGATCAA; Reverse: 
ACGGATGTCCATGCTGTAGAAGCTA; E 
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LANE: Forward: ACTGCGTGGCGAATGTAAACGT; Reverse: 
CCGTTTTCGAAGATGCGCTGCA;  
EIF2S3: Forward: TGCTCCAGGCGGTCTTATTGGAGTT; Reverse: 
TCAGGTAAAGCTCCGACTGCACCA;  
ANAX3: Forward: TCGCTCGCAGTTTGTTCGCAGT; Reverse: 
TGTTCCTCGGTGTCCAACCCAGAT.  
 
Data and statistical analysis  
 
The RT-PCR and luciferase reporter results are presented as the mean ± SD of at least three 
independent experiments. Differences in the expression of mRNA and miRNA were 
determined using a two-tailed non-parametric Mann-Whitney U-test within the GraphPad 
Prism 5 (http://www.graphpad.com). P values of < 0.05 were considered significant and are 
indicated with asterisks. .  
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Results 
 
Patient Groups 
 
Transcriptomics studies were performed in the circulating CD4+ and C8+ T-cells obtained from 
12 individuals with severe asthma, 4 non-severe asthmatics and 8 healthy controls individuals 
(Table 1) which had been sanctioned by the Royal Brompton and Harefield NHS Trust Ethics 
committee. Severe asthma was defined according to the American Thoracic Society major 
criteria of needing either continuous or near continuous oral corticosteroids or high dose 
inhaled corticosteroids (2,000 μg beclomethasone-equivalent per day or more) or both in order 
to achieve a level of mild-moderate persistent asthma, and by 2 or more minor criteria of 
asthma control 15.  Severe asthma patients underwent the Royal Brompton severe asthma 
protocol, in order to confirm the diagnosis and to maximise treatments. Patients with non-
severe asthma were those who did not fall into the severe asthma category and who used 0–
1000 μg inhaled beclometasone or equivalent dosage per day with perfect control of their 
asthma. All patients showed either an improvement in baseline FEV1 of ≥12% over baseline 
values after inhalation of 400 μg of salbutamol aerosol, or the presence of bronchial 
hyperresponsiveness defined by methacholine PC20 of <4 mg/ml. Current and ex-smokers of 
>5 pack-years were excluded. Healthy control volunteers with no diagnosis of asthma and with 
a negative PC20 (>16 mg/ml), using no medications and never-smokers, were also recruited as 
the comparative group.  
 
Characterisation of T-cell populations 
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Circulating blood (50ml) was obtained from control non-asthmatic individuals or patients with 
non-severe and severe asthma. Prior to negative-selection, measurement of the total number of 
peripheral blood mononuclear cells in control, non-severe and severe asthmatics showed no 
significant difference with 97.6 ± 7.7,  XX.X ± X.X and 127.0 ± 30 (x 106 cells), respectively. 
FACS analysis showed that antibody-based negative selection resulted in the production of 
highly purified (> 98%) CD4+ and CD8+ T-cells. Following their isolation, we once again 
observed no significant difference in the number of CD4+ T-cells (11.2 ± 1.8, XXX ± XX and 
11.9 ± 1.0 (x 106)) and CD8+ T-cells (5.5 ± 0.6, XXX ± XX and 4.7 ± 0.6 (x 106)) in control, 
non-severe and severe asthmatic patients, respectively.  
 
Severe asthma is associated with changes in mRNA expression in CD4+ and CD8+ T-cells 
 
Measurement of the profile of mRNA expression using Affymetrix microarrays showed that 
this differed between healthy and severe asthmatic patients but not non-severe asthmatics. 
These initial studies were performed using the eight control individuals, 4 non-severe 
asthmatics and 8 severe asthmatics (Table 1: Patients 1 - 8). In the case of the CD4+ T-cells, 
we identified a relatively small number of transcripts (n = 40) that were up-regulated (see 
Table E1 in the online data supplement) and none that were down-regulated by >1.5-fold 
(FDR < 0.05; p < 0.05) in severe asthmatics versus controls. In contrast, with CD8+ T-cells we 
observed 1359 up-regulated genes (see Table E2 in the online data supplement) and 207 down-
regulated genes (see Table E3 in the online data supplement) in the samples obtained from 
severe asthmatics (> 1.5 fold; FDR < 0.05; p < 0.05).  
 
The general validity of these microarray observations in the severe asthmatic samples was 
assessed using qRT-PCR. Since the initial microarray studies were performed using a group of 
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severe asthmatics that contained a ratio of 7:1 of female:male, we included an additional 4 
samples obtained from males with severe asthma to account for potential gender bias. These 
studies were able to confirm the increase in expression of 9 of 10 mRNAs examined in CD4+ 
T-cells and in 13 of 16 mRNAs in CD8+ T-cells (Tables 2 and 3). These included 
bactericidal/permeability-increasing protein (BPI), carcinoembryonic antigen-related cell 
adhesion molecule (CEACAM)-6/8, lipocalin 2 (LCN), lactotransferrin (LTF), S100 calcium 
binding protein–P/A8/A9/A12, chitinase 3-like 1 (CHI3L1), leukocyte elastase (ELA2), 
annexin A3 (ANAX3) and arginase (ARG).  
 
As might be predicted from the microarray data, we observed only a small number of mRNAs 
whose expression profile was changed in non-severe asthmatics versus non-asthmatics 
controls  (Supplemental Table E4). This included 2 of 10 mRNAs examined in CD4+ T-cells 
and in 5 of 15 mRNAs in CD8+ T-cells (Supplemental Table E4). 
 
Pathway analysis shows activation of CD8+ but not CD4+ T-cells in severe asthmatics 
 
To identify the pathways that were either activated or inhibited in the CD4+ and CD8+ T-cells 
from severe asthmatics we analysed the changes in profile of mRNA expression using the 
Ingenuity Systems software (http://ingenuity.com/) (Table 4). Significantly, this showed an 
upregulation in the expression of those transcripts involved in multiple inflammatory and other 
signalling pathways in CD8+ T-cells from severe asthmatics. These included those involved in 
T-cell activation (e.g. T-cell receptor signalling, NFAT transcription factor pathway, ICOS-
ICOSL and CD28 co-stimulation as well as the pathways involved in the regulation of IL-2 
expression in activated and anergic T lymphocytes) and inflammation (LPS-stimulated 
MAPK, JAK/Stat and NF-B signalling pathways). A number of pathways that are commonly 
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associated with asthma including IL-3, IL-4 and IL-9 were also activated, as was 
glucocorticoid signalling.  In contrast, only the vitamin D pathway was up-regulated in CD4+ 
T-cells, whilst no pathways were shown to be down-regulated in either CD4+ or CD8+ T-cells. 
 
Subsequent analysis aimed to identify mRNAs that were associated with differences in the T 
cell phenotype from severe asthmatics compared to control non-asthmatics. Comparison of the 
two data sets showed that 23 genes were up-regulated in both the CD4+ and CD8+ T-cell 
populations, but no genes that were down-regulated (Table 2). Prominent amongst the up-
regulated mRNAs were members of the S100 calcium binding and carcinoembryonic antigen-
related cell adhesion (CEACAM) molecule family. Examination of those mRNAs that had the 
largest fold changes also highlighted the potential importance of the S100 and CEACAM 
families in both CD4+ T-cells or CD8+ T-cells (Table 3). Interestingly, two proteins that have 
recently been linked to asthma, arginase 1 16 and chitinase 3-protein 1 17 were also shown to be 
increased in CD8+ T-cells (Table 2 and 3).  
 
Severe asthma is associated with reduced miRNA expression of miR-146a/b in CD4+ and 
CD8+ T-cells 
 
Previous investigations have shown that a number of miRNAs including miR-21, miR-132, 
miR-146a, miR-150, miR-155 and miR-326 are important regulators of the differentiation, 
proliferation and activation of immune cells 18-20.  To determine whether miRNAs might 
regulate the changes in mRNA expression, we measured the expression of these immune 
related miRNAs (Table 5). These studies showed that only the expression of miR-146a and 
miR-146b was reduced by 50 – 80 % and that this occurred in both CD4+ and CD8+ T-cells 
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from severe asthmatics (Table 5). Significantly, we also observed a selective reduction of ~ 
30% in the expression of miR-18a-5p in CD8+ T-cells. 
 
Since it might be expected that a reduction in miRNA expression miR-146a and miR-146b 
would lead to increased expression of their predicted mRNA targets we examined this 
possibility using the miRNA target prediction programme, TargetScan 
(http://www.targetscan.org/). Bioinformatics analysis showed an enrichment of miR-28a-5p (p 
= 0.026) and miR-146 (p = 0.13) targets in those mRNAs that were down-regulated in CD8+ 
T-cells. As a result of the small number of differentially regulated mRNAs in CD4+ T cells, it 
was not possible to determine whether targets for miR-146 were enriched. 
 
Severe asthma is associated with widespread changes in the expression of long non-
coding RNAs in CD8+ T-cells 
 
In addition to the miRNA family of short non-coding RNAs (< 200 nucleotides), there is now 
accumulating evidence that long non-coding RNAs (> 200 nucleotides) regulate multiple 
biological responses and that changes in their expression is related to the development of 
disease 21;22. At the present time, long non-coding RNAs (lncRNAs) can be broadly divided 
into 4 families based upon their sequence and relative position to the exonic regions of protein 
coding sequences and includes pseudogenes, natural antisense (to exonic regions), intronic 
lncRNAs and intergenic lncRNAs. To identify novel lncNAs, we used Emsembl 
(http://www.ensembl.org/index.html) to determine the genomic position of those probesets 
from the Affymetrix U133 Plus 2.0 microarray which i) did not match known protein coding 
genes and ii) were significantly changed (> 1.5 fold; FDR < 0.05; p < 0.05) in the CD4+ and 
CD8+ T-cells in severe asthma. Of relevance, a recent publication has indicated that these 
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probesets are able to detect up to 43% of the 5446 predicted lncRNAs in the human genome 20. 
This approach identified a small number of lncRNAs that were down-regulated in CD4+ T-
cells (see Supplemental Table E5 in the online data supplement) including 4 intergenic 
lncRNAs and 2  intronic lncRNAs. Of these lncRNAs, only a single transcript entitled 
AC090517.2 has been manually annotated by the Havana project team at the Wellcome Trust 
Sanger Institute (Supplemental Table E5). In the case of CD8+ T-cells, we identified 167 
potential lncRNAs that we significantly changed in severe asthma (see Supplemental Table E6 
in the online data supplement). These included 5 antisense sequences (4 up-regulated and 1 
down-regulated), 4 pseudogenes (3 up-regulated and 1 down-regulated), 44 intergenic lncRNA 
(28 up-regulated and 16 down-regulated ) and 114 intronic lncRNAs (106 up-regulated and 8 
down-regulated). In this case, 19 of these transcripts have been manually annotated and 
include 1 antisense sequence, all 4 pseudogenes and 14 intergenic lncRNAs (Table 6). Overall, 
this bioinformatics analysis has shown for the first time, that changes in lncRNA expression is 
associated with the severe asthma in circulating T-cells although their function remains to be 
determined.  
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Discussion 
 
In this report, we have compared the profile of mRNA expression in the circulating CD4+ 
and CD8+ T-cells from healthy individuals, non-severe asthmatics and severe asthmatics 
using microarray and qRT-PCR.  In contrast to previous studies that have implicated Th2 
CD4+ in driving the inflammatory response in asthma, we showed no major changes in the 
profile of mRNA expression in non-severe asthmatics and only a relatively small number of 
mRNAs that were up-regulated in CD4+ T-cells from severe asthmatics. whilst Pathway 
analysis indicated that these circulating CD4+ T-cells from severe asthmatics were non-
activated. In contrast, there were widespread changes in the expression of mRNAs in 
circulating CD8+ T-cells obtained from severe asthmatics including the pathways associated 
with T-cell activation and the allergic inflammatory response. Since these changes were not 
observed in non-severe asthmatics this indicated that the changes in mRNA expression in 
circulating CD8+ T-cells is related to the severity of the asthma and not asthma per se.  
 
 
Examination of the individual mRNAs showed 23 mRNAs were up-regulated in both CD4+ 
and CD8+ T-cells from severe asthmatics including members of the S100 calcium binding and 
carcinoembryonic antigen-related cell adhesion (CEACAM) molecule family. The calgranulin 
family of S100 calcium binding proteins is composed of 3 members, S100A8, S100A9 and 
S100A12 which were all shown to be up-regulated in CD4+ and CD8+ T-cells. Interestingly, 
increased calgranulin expression is linked to the development of rheumatoid arthritis, 
inflammatory bowel disease and atherosclerosis 24;25, is released from 
neutrophils/macrophages and is thought to induce an inflammatory response through 
activation of TLR4 and receptor for advanced glycosylation (RAGE) 26. Much less is known 
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about the immunoglobulin-related glycoprotein CEACAM family, of which CEACAM-6 and 
CEACAM-8 are upregulated in both CD4+ and CD8+ T cells, although they have been 
implicated in T-cell proliferation 27.  
 
Specific mRNAs up-regulated in CD8+ T-cells from severe asthmatics included chitinase 3-
protein 1 and arginase.  Chitinase 3-protein-1, which is also known as YKL-40 (humans) and 
BRP-39 (mice), is up-regulated in many inflammatory diseases including osteoarthritis, 
rheumatoid arthritis, sarcoidosis, inflammatory bowel disease, idiopathic pulmonary fibrosis 
and solid malignancy 17;28;29. Significantly, it is also elevated in serum and lung 
macrophages/epithelium of individuals with asthma, where expression correlates positively 
with severity of disease 30;31. Furthermore, mouse studies have shown that YKL-40 is crucial 
in the initiation and effector stage of Th2-driven inflammation and airway re-modelling in 
models of allergen-induced asthma and in IL-13 transgenic mice 32.  As with humans, the 
animal studies showed that the elevation in chitinase 3-protein-1 expression was 
predominately associated with lung epithelium and macrophages 32.  Arginase is a key 
metalloenzyme of the urea cycle that converts L-arginine into L-ornithine and urea. It is 
known to be elevated in asthmatic patients as well as various animal models of asthma 16. It 
has been speculated that increased arginase deprives nitric oxide synthase of arginine and 
thereby prevents the production of nitric oxide (NO), a key bronchodilator and anti-
inflammatory in asthma.   
 
Having demonstrated changes in the mRNA expression, we investigated whether this might be 
mediated by changes in miRNA expression. There is now accumulating evidence that miRNAs 
regulate the proliferation, differentiation and activation of T-cells. Thus, studies involving 
DICER knockout (an RNase III enzyme that is crucial to the production of mature miRNAs) in 
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T-cell development showed that miRNAs are important in T-cell proliferation and the 
generation of the Th2 phenotype and FoxP3+ CD4+ T-regulatory (Treg) cells 18-20. Subsequent 
investigations aimed at characterising the role of individual miRNAs have implicated the miR-
17~92 cluster in early T-cell proliferation, miR-155 in the development of the Th2 and Treg 
phenotype and miR-181a as a inhibitor of CD8+ T-cell function 18-20. Both miR-155 and miR-
181a have also been implicated in the regulation of acute response in activated CD4+ T-cells 
including the release of IL-2 and IFN-.  In addition, recent animal studies have shown 
increased expression of miR-21 expression in the lungs during ovalbumin-, fungal- and IL-13-
induced allergic airway inflammation 33 and increased miR-126 expression in a house dust 
mite-induced model of asthma 34. 
 
Our comparison of the expression of these immune related miRNA showed no changes in 
expression of members of the miR-17~92 cluster, miR-155, miR-181a, miR-21 or miR-126 in 
CD4+ and CD8+ T-cells from severe asthmatics although we observed significant down-
regulation in expression of miR-146a and miR-146b. Interestingly, there are an increasing 
number of publications that demonstrate a central role for miR-146a in the regulation of 
immune responses. 35-40 and in the development of inflammatory disease such as rheumatoid 
arthritis, osteoarthritis, systemic lupus erythematosus and chronic obstructive pulmonary 
disease 41;42.  However, although we observed significant down-regulation of miR-146a/b in 
both CD4+ and CD8+ T-cells, only CD8+ T-cells showed widespread changes in the profile of 
mRNA expression. This would imply that miR-146a/b alone are not responsible for changes in 
the mRNA profile in CD8+ T-cells, a conclusion that is support by the fact that there was only 
a bias towards targets of miR-146a/b (p = 0.13). Significantly, we also observed selective 
down-regulation of miR-28-5p in CD8+ T-cells and bioinformatics analysis showed an 
enrichment of miR-28a-5p (p = 0.026) targets in those mRNAs that were down-regulated in 
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CD8+ T-cells. At the present time, virtually nothing is known regarding the biological function 
of miR-28-5p and subsequent studies will need to investigate its function in CD8+ T-cells. 
 
Having shown altered expression of mRNAs and miRNAs, we proceeded to investigate 
whether severe asthma was also associated with changes in expression of lncRNAs. LncRNAs 
can be broadly divided into natural antisense, pseudogenes, long intronic ncRNAs and long 
intergenic ncRNA. Despite their widespread expression, their importance in the regulation of 
multiple physiological and pathological response is only now emerging 21;22. Thus, recent 
reports have demonstrated that expression of long intergenic ncRNA expression is cell- and 
developmentally-specific and mediated through activation of common transcription factors 
including p53, NF-B, Sox2, Oct4 and Nanog 43. Our initial analysis of the profile of lncRNA 
expression showed that severe asthma was also correlated with widespread changes in the 
expression of natural antisense, pseudogenes, long intronic ncRNAs and long intragenic 
ncRNAs in circulating CD8+ T-cells but not CD4+ T-cells. This observation indicates for the 
first time, that the changes in mRNA expression and subsequent T-cells function might be 
regulated by lncRNAs.   
 
In summary, using a transcriptomics based approach we have demonstrated that circulating 
CD8+-T-cells from severe asthmatics but not non-severe asthmatics have a transcript 
expression profile associated with an activated phenotype and shown that these changes might, 
in part, be mediated through alterations in non-coding RNA expression. In contrast, there was 
little evidence to suggest activation of circulating CD4+ T-cells in either non-severe or severe 
disease despite the fact that tissue CD4+ Th2 cells have previously been linked with the 
asthmatics phenotype. Clearly, and to determine the activation state of circulating CD4+ and 
CD8+ T-cells in patients with mild to moderate asthma. since antigen specific T-cells are 
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believed to compartmentalize to local or regional lymph, these observations could be the result 
of circulating (spilled over) factors and may not reflect in situ activation and effector function 
for these cells. It will therefore be important to confirm these observations using lung derived 
T-cells. In addition, it will also be important to examined whether the activation of CD8+ T-
cells observed at the transcriptional levels is reflected by changes in effector function and/or 
the effect of therapy. However, given the increasing evidence to suggest that viral infection is 
important to both asthma development in early life and subsequent exacerbations 44;45 and the 
role of CD8+ T-cells in the immune response to viral infection, it might therefore be speculated 
that chronic activation of CD8+ might contribute towards the symptoms observed in severe 
asthma. If confirmed, this would suggest that targeting either the activation CD8+ cells, or their 
effector functions, might provide a novel therapeutic approach to the treatment of severe 
asthma.   
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Table 1  Patient Data 
 
 
Patient  Age 
(yrs) 
Gender 
(M/F) 
FEV1  
(% 
predicted) 
FVC  
(% predicte 
d) 
PC20 Medication 
Control       
1 39 M 78 76 >16mg/ml None 
2 25 F 103 107 >16mg/ml None 
3 26 F 105 115 >16mg/ml None 
4 46 M 92 105 >16mg/ml None 
5 33 M 78 77 >16mg/ml None 
6 33 F 116 115 >16mg/ml None 
7 31 F 85 96 15.67mg/ml None 
8 56 M 111 111 >32mg/ml None 
Mean ± SEM 36 ± 4 4/4 96 ± 5 100 ± 6    
       
 
Non-Severe 
Asthma  
 
    
1 23 M 82 98 Not done Becotide, Ventolin 
2 44 F 87 92 0.52 mg/ml Fl 
3 35 M 77 89 6.27 mg/ml Becotide, Ventolin 
4 23 F 84 81 0.17 mg/ml Salbutamol 
Mean ± SEM 31 ± 5 2/2 83 ± 2 90 ± 2    
 
 
Severe Asthma  
 
    
1 55 F 82 105 1.09 mg/ml Fl, Oxis, Loradine, Beconase 
2 21 F 105 101 Not done Pr, Se, Si, Phyllocontin, Ventolin 
3 32 M 98 113 0.01 mg/ml Pr, Se, Montelukast, Ventolin, Phyllocontin, Fl 
4 55 F 65 81 0.10 mg/ml Pr, Sp, Se, Methotrexate, Fosamax, Folic acid, Cocodamol 
5 54 F 44 61 Not done Pr, Sy, Montelukast,  Omeprazole, Uniphyllin, Bricanyl 
6 54 F 55 65 Not done Pr, Co, Ce, Terbutaline, Bu, Aminophylline SR, Formoterol 
7 45 F 71 105 Not done Pr, Se, Fl, Metformin, Nexium, Tramacet, Valsartan, Amitriptyline 
8 42 F 33 94 Not done Pr, Se, Aminophylline,  Doxycycline, Tiotropium 
9 47 M 63 81 Not done Se, Uniphylline, Fosamax, Ventolin, Atrovent 
10 39 M 63 73 Not done Sy, Loratine, Beconase, Uniphylline 
11 61 M 57 98 Not done Pr, Sy, Fl, Omerprazole, Atorvastin,  
12 52 M 83 97 Not done Sy, Betnasal 
Mean ± SEM 46 ± 3 5/7 68 ± 6 90 ± 5     
 
 
Abbreviations: Bu – budesonide; Ce – cetirizine; Co – combivent; Fl – flixotide; Pr – prednisolone; Se – seretide; Si – singular; Sp – spiriva; 
Sy – symbicort;  
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Table 2   Common mRNAs expression changes in both CD4
+
 and CD8
+
 T-cells in severe asthma. This table lists those mRNAs whose 
expression was increased in both the CD4
+
 and CD8
+
 T -cells from severe asthmatics  when compared to non-asthmatic. Microarray data is 
denoted as fold change (FC) against non-asthmatics controls and is the mean of 8 individual patients. These values are derived from 
Supplemental Table E1 and E2 in the on-line supplemental tables and are those genes that demonstrated an FDR < 0.05  -  associated p-values 
are given in brackets. Changes in mRNA expression were confirmed by qRT-PCR, which was normalised against 18S and expressed as fold 
changes over non-asthmatics controls. In the case of the  qRT-PCR data, statistical significant against non-asthmatics controls was determined 
using a two-tailed non-parametric Mann-Whitney U-test.   These values are the mean of 12 individual patient samples and the p values are 
indicated in the brackets 
 
  CD4
+
 T-cells CD8
+
 T-cells 
Gene Symbol Gene Name Microarray 
(FC) 
qRT-PCR 
(FC) 
Microarray 
(FC) 
qRT-PCR 
(FC) 
 
BPI bactericidal/permeability-increasing protein 2.6 (< 0.001) 21.7 (0.019) 2.8 (< 0.001) 29.1 (0.001) 
CAMP cathelicidin antimicrobial peptide 3.3 (< 0.001) 12.4 (0.065) 2.1 (0.017) 5.9 (0.016) 
CASK Peripheral plasma membrane protein CASK 1.7 (< 0.001) - 1.8 (< 0.001) - 
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6  2.4 (< 0.001) 29.1 (0.012) 2.9 (< 0.001) 4.6 (0.012) 
CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 5.6 (< 0.001) 20.2 (0.023) 4.4 (< 0.001) 3.7 (0.023) 
CFLAR FLAME-1 1.6 (< 0.001) - 2.4 (0.019) - 
GCA grancalcin, EF-hand calcium binding protein 2.6 (< 0.001) - 2.6 (0.002) - 
LCN2 lipocalin 2 4.7 (< 0.001) 17.0 (0.015) 2.4 (< 0.001) 14.8 (0.01) 
LOC23117 KIAA0220-like protein 2.4 (< 0.001) - 3.3 (0.007) - 
LOC728358 defensin, alpha 1 6.2 (< 0.001) - 2.3 (0.004) - 
LTF lactotransferrin 5.0 (< 0.001) 21.1 (0.012) 2.1 (< 0.001) 2.5 (0.154) 
POLR2J2 DNA directed RNA polymerase II polypeptide J-related 1.9 (< 0.001) - 3.8 (0.001) - 
RETN resistin 1.7 (< 0.001) - 2.3 (0.005) - 
RNASE3 ribonuclease, RNase A family, 3 (eosinophil cationic protein) 2.0 (< 0.001) - 1.8 (0.005) - 
S100A12 S100 calcium binding protein A12 4.7(< 0.001)  27.1 (0.0078) 2.4 (0.051)   6.5 (0.031) 
S100A8 S100 calcium binding protein A8 4.8 (< 0.001) 15.3 (0.015) 2.0 (< 0.001)  28.3 (0.006) 
S100A9 S100 calcium binding protein A9 5.0 (< 0.001) 19.5 (0.019)  1.9 (0.011) 2.7 (0.070) 
S100P S100 calcium binding protein P 3.3 (< 0.001) 21.2 (0.008) 2.1 (0.008) 18.4 (0.001) 
SLC38A2 Amino acid transporter system A2 (ATA2) 1.6 (< 0.001) - 1.6 (< 0.001)  - 
SPATA13 spermatogenesis associated 13 1.7 (< 0.001) - 1.5 (0.001) - 
SRGN serglycin 2.0 (< 0.001) - 1.8 (0.016) - 
TNIP1 TNFAIP3 interacting protein 1 1.6 (< 0.001) - 1.7 (< 0.001)  - 
UGCG UDP-glucose ceramide glucosyltransferase(UGCG) 2.0 (< 0.001) - 2.5 (< 0.001) - 
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Table 3   mRNAs expression showing highest fold-change in CD4
+
 and CD8
+
 T-cells in severe asthma. This table lists those mRNAs 
whose expression showed the largest fold-change increase in either CD4
+
 and CD8
+
 T -cells when compared to non-asthmatic controls. 
Microarray data is denoted as fold change (FC) against non-asthmatics controls and is the mean of 8 individual patients. These values are 
derived from Supplemental Table E1 and E2 in the on-line supplemental tables and are those genes that demonstrated an FDR < 0.05  -  
associated p-values are given in brackets.  Changes in mRNA expression were confirmed by qRT -PCR, which was normalised against 18S 
and expressed as fold changes over non-asthmatics controls. In the case of the qRT-PCR data, statistical significant against non-asthmatics 
controls was determined using a two-tailed non-parametric Mann-Whitney U-test.   These values are the mean of 12 individual patient 
samples and the p values are indicated in the brackets.  
Gene Symbol Gene Name Array 
(FC) 
RT-PCR 
(FC) 
    
CD4
+
 T-cells    
LOC728358 defensin, alpha 1 6.6 (< 0.001)  - 
CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 5.6 (< 0.001) 20.2 (0.023) 
LTF lactotransferrin 5.0 (< 0.001) 21.1 (0.012) 
S100A9 S100 calcium binding protein A9 5.0 (< 0.001) 19.5 (0.019) 
S100A8 S100 calcium binding protein A8 4.8 (< 0.001) 15.3 (0.015) 
LCN2 lipocalin 2 4.7 (< 0.001) 17.0 (0.015) 
S100A12 S100 calcium binding protein A12 4.7 (< 0.001) 27.1 (0.008) 
DEFA4 defensin, alpha 4, corticostatin 4.3 (< 0.001) - 
MMP8 MMP-8 (collagenase 2) 3.6 (< 0.001) - 
S100P S100 calcium binding protein P 3.3 (< 0.001) 21.2 (0.008) 
CAMP cathelicidin antimicrobial peptide 3.3 (< 0.001) 
 
12.4 (0.645) 
MNDA myeloid cell nuclear differentiation antigen 2.7 (< 0.001) - 
BPI bactericidal/permeability-increasing protein 2.6 (< 0.001) 21.7 (0.019) 
GCA grancalcin, EF-hand calcium binding protein 2.6 (< 0.001) - 
ZNF749 zinc finger protein 749 2.5 (< 0.001) - 
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6  2.4 (< 0.001) 29.1 (0.012) 
LOC23117 KIAA0220-like protein 2.4 (< 0.001) - 
STOM stomatin 2.3 (< 0.001) - 
ALOX5 Arachidonate 5-lipoxygenase 2.2 (< 0.001) - 
UGCG UDP-glucose ceramide glucosyltransferase 2.0 (< 0.001) - 
    
CD8
+
 T-cells    
CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 4.4 (< 0.001) 
 
3.7 (0.023) 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 3.9 (< 0.001) 
 
4.8 (0.019) 
LTF lactotransferrin 3.8 (< 0.001) 2.5 (0.154) 
ELA2 Leukocyte elastase (Neutrophil elastase) 3.7 (0.002) 12.7 (0.013) 
CD24 CD24 molecule 3.6 (< 0.001) 3.5 (0.015) 
LCN2 lipocalin 2 3.3 (< 0.001) 14.8 (0.01) 
EIF2S3 
eukaryotic translation initiation factor 2, subunit 3 gamma, 
52kDa 3.3 (0.045) 
 
1.5 (0.232)  
ANXA3 annexin A3 3.2 (0.001) 9.6 (0.008)  
ARG1 arginase, liver 3.2 (0.001) 4.0 (0.04) 
SEPT6 septin 6 3.1 (0.010) - 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 3.1 (0.013) - 
CEACAM6 
carcinoembryonic antigen-related cell adhesion molecule 6 (non-
specific cross reacting antigen) 2.9 (< 0.001)  
 
4.6 (0.030) 
AZU1 Azurocidin 2.9 (0.003) - 
LEF1 lymphoid enhancer-binding factor 1 2.9 (0.026) - 
BPI bactericidal/permeability-increasing protein 2.8 (< 0.001) 29.1 (0.001) 
SF1 splicing factor 1 2.8 (0.030) - 
SAMHD1 SAM domain and HD domain 1 2.7 (0.006) - 
S100B S100 calcium binding protein B 2.7 (0.046) - 
TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) 2.7 (0.002) - 
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Table 4   Pathway Analysis in CD4
+
 and CD8
+
 T-cells in severe asthma. Circulating CD4
+
 and CD8
+
 T -cells were isolated from 8 
non-asthmatics control and 8 severe asthmatics and mRNAs expression was determine using U133 Affymetric microarrays. The mRNAs 
that showed significant change were analysed using the Ingenuity Systems software (http://ingenuity.com/) and those pathways showing a 
significant increase are listed. 
 
 
Gene Set Name 
 
P value 
CD4
+
 T-cells 
 
 
VDR/RXR Activation 4.80E-04 
  
CD8
+
 T-cells 
  
Role of NFAT in Regulation of the Immune Response 7.80E-06 
Molecular Mechanisms of Cancer 3.20E-05 
Death Receptor Signaling 3.70E-05 
T  Cell Receptor Signaling 3.90E-05 
Glucocorticoid Receptor Signaling 4.20E-05 
LPS-stimulated MAPK Signaling 7.20E-05 
Apoptosis Signaling 8.80E-05 
Acute Myeloid Leukemia Signaling 1.00E-04 
B Cell Receptor Signaling 1.10E-04 
CD40 Signaling 1.30E-04 
JAK/Stat Signaling 1.30E-04 
IL-8 Signaling 1.30E-04 
PPARa/RXRa Activation 1.50E-04 
NF-KappaB Signaling 1.90E-04 
iCOS-iCOSL Signaling in T  Helper Cells 2.80E-04 
IL-9 Signaling 2.80E-04 
Angiopoietin Signaling 3.80E-04 
EIF2 Signaling 4.10E-04 
IL-3 Signaling 4.50E-04 
PDGF Signaling 4.50E-04 
Prolactin Signaling 4.50E-04 
GM-CSF Signaling 4.50E-04 
IL-4 Signaling 7.30E-04 
Regulation of IL-2 Expression in Activated and Anergic T  
Lymphocytes 7.60E-04 
CD28 Signaling in T  Helper Cells 9.50E-04 
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Table 5   miRNA expression levels in circulating CD4
+
 and CD8
+
 T-cells from non-asthmatics controls and severe asthmatics. 
Circulating CD4
+
 and CD8
+
 T-cells were isolated from 8 non-asthmatics control and 8 severe asthmatics and the levels of individual 
miRNAs were determined by TaqMan qRT -PCR. Baseline expression levels are expressed as dCT and have been normalised against 
RNU44. Differences between control and severe asthmatics is expressed as fold change from contro l. All values are the mean ± SD of 8 
individual patient samples and statistical differences were evaluated using the Mann-Whitney U-test.   
 
 
miRNA CD4
+
 T-cells 
 
CD8
+
 T-cells 
Baseline 
Expression 
(dCT ) 
Fold change from control (%) Baseline 
Expression 
(dCT ) 
 
Fold change from control (%) 
 Control  Control  Asthmatics p-value Control Control  Asthmatics p-value  
 
miR-16 -1.2 ± 0.5 106.2 ± 32.3 84.3 ± 43.7 0.302 -1.5 ± 0.5 108.1 ± 51.1 73.4 ± 19.9 0.069 
miR-17-5p 4.1 ± 0.5 107.0 ± 40.0 105.5 ± 32.1 0.980 3.7 ± 0.8 118.4 ± 73.4 70.0 ± 20.9 0.243 
miR-21 -0.8 ± 0.5 108.0 ± 39.8 125.3 ± 42.7 0.428 0.1 ± 0.5  108.7 ± 53.0 100.0 ± 35.0 0.739 
miR-26a 0.1 ± 0.5 105.7 ± 33.4 84.8 ± 30.7 0.242 0.2 ± 0.8 122.4 ± 98.6 72.0 ± 70.2 0.149 
miR-28-5p 5.1 ± 0.3 97.4 ± 11.9 106.8 ± 23.6 0.637 4.4 ± 0.5 104.9 ± 32.3 68.7 ± 32.1 0.046 
miR-29a -0.2 ± 0.5 104.5 ± 29.7 105.0 ± 38.7 0.926 -0.2 ± 0.5 105.3 ± 33.4 89.8 ± 33.9 0.360 
miR-106a 3.9 ± 0.5  104.3 ± 33.9 109.4 ± 43.7 0.982 3.5 ± 1.1 124.4 ± 94.6 70.4 ± 25.4 0.159 
miR-126 6.1 ± 2.1 276.9 ± 351.9 59.4 ± 57.0 0.784 6.0 ± 5.0 190.0 ± 187.1  30.9 ± 23.9 0.687 
miR-142-3p -4.0 ± 0.3 101.2 ± 17.0 103.3 ± 30.5 0.949 -3.8 ± 0.5 104.6 ± 31.3 90.7 ± 27.0 0.392 
miR-142-5p 0.0 ± 0.3 100.9 ± 13.5 104.8 ± 22.3 0.952 0.0 ± 0.5 103.9 ± 32.6 95.0 ± 32.1 0.515 
miR-146a 3.2 ± 0.3 109.2 ± 35.8 59.4 ± 29.7 0.021 4.9 ± 3.7 135.2 ± 93.3 47.5 ± 31.8 0.049 
miR-146b 2.1 ± 0.3 111.3 ± 38.4 53.0 ± 32.9 0.010 4.1 ± 3.2 122.4 ± 73.4 51.3 ± 23.3 0.049 
miR-150 -4.8 ± 0.3 100.3 ± 8.0 102.9 ± 23.9 0.641 -4.4 ± 0.3 102.9 ± 23.6 93.6 ± 17.2 0.491 
miR-155 2.8 ± 0.5 104.7 ± 31.0 129.0 ± 23.1 0.105 2.2 ± 0.5 105.2 ± 33.4 76.3 ± 35.8 0.099 
miR-155* 13.0 ± 1.1 120.4 ± 66.8 148.7 ± 82.7 0.601 12.4 ± 1.1 129.3 ± 94.3 114.7 ± 74.2 0.784 
miR-181a 3.1 ± 0.3 101.1 ± 15.1 86.9 ± 22.3 0.159 2.7 ± 0.8 117.8 ± 70.2 77.3 ± 26.0 0.239 
miR-196a 11.6 ± 1.1 120.8 ± 71.6 136.5 ± 41.9 0.351 8.5 ± 0.5 108.2 ± 39.5 145.8 ± 15.1 0.608 
miR-223 2.4 ± 1.3 150.3 ± 130.4 170.8 ± 93.8 0.364 0.4 ± 1.3 171.9 ± 230.8 95.6 ± 45.3 0.673 
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Table 6  Changes in the expression of long non-coding RNAs in CD8
+
 T-cells in severe asthma.. This table lists those long non-coding 
RNAs that have been manually annotated in the Ensembl database and whose expression was significantly changed in circulating CD8
+
 T -cells 
obtained from severe asthmatics compared with healthy controls.  All values are the mean of 8 individual patient samples and statistical 
differences were evaluated using the Mann-Whitney U-test where * p < 0.05 
 
Probeset 
Class of long non-
coding RNA Ensembl Gene ID Transcript Name p-value 
Fold 
Change 
220459_at Antisense ENSG00000215424 MCM3APAS 
 
minichromosome maintenance 
complex component 3 associated 
protein antisense RNA 0.00014 1.73 
1557008_at Intergenic ENSG00000248908 RP11-730N24.1  0.00015 -1.80 
1556453_at Intergenic ENSG00000229727 AC013460.1  0.00107 -1.59 
210794_s_at Intergenic ENSG00000214548 MEG3 
maternally expressed 3 (non-
protein coding) 0.00002 -1.54 
215011_at Intergenic ENST00000413987 SNHG3 
small nucleolar RNA host gene 3 
(non-protein coding) 0.00148 1.53 
1553449_at Intergenic ENSG00000180422 C16orf81 
chromosome 16 open reading 
frame 81 0.00000 -1.86 
228913_at Intergenic ENSG00000170919 
XXyac-R12DG2.2-
010  0.00000 1.56 
1554447_at Intergenic ENSG00000225470 NCRNA00183 non-protein coding RNA 183 0.00152 2.27 
223725_at Intergenic ENSG00000240288 GHRLOS 
ghrelin opposite strand (non-protein 
coding) 0.00030 1.53 
243656_at Intergenic ENSG00000215447 BX322557.10  0.00021 -1.60 
1563088_a_at Intergenic ENSG00000215458 AP001053.11  0.00005 -1.53 
1557505_a_at Intergenic ENSG00000251153 AL049776.2  0.00000 1.67 
241270_at Intergenic ENSG00000250233 AC015802.2  0.00002 -1.62 
1564211_at Intergenic ENSG00000246223 C14orf64  0.00115 1.67 
1564426_x_at Intergenic ENSG00000247397 AC130352.1  0.00151 -1.95 
237544_at Pseudogene ENSG00000107679 PLEKHA1 
pleckstrin homology domain 
containing, family A pseudogene 0.00003 1.81 
1562250_at Pseudogene ENSG00000176993 AL590233.1 Known pseudogene 0.00080 1.99 
1555890_at Pseudogene ENSG00000170356 OR2A20P 
olfactory receptor, family 2, 
subfamily A, member 20 
pseudogene  0.00095 1.70 
244071_at Pseudogene ENSG00000188573 FBLL1 fibrillarin-like 1 0.00141 -1.74 
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